91ĸƵ

91ĸƵ Surgical’s Martin Frost wins Executive of the Year award

~ Martin Frost’s vision and leadership recognised by panel of independent industry experts, through “Executive of the Year” award at the 2019 MedTech Insight Awards.

~ Martin Frost’s vision and leadership recognised by panel of independent industry experts, through “Executive of the Year” award at the 2019 MedTech Insight Awards.

91ĸƵ is proud to announce that our Chief Executive Officer has been honoured with the Executive of the Year award at the . Held in partnership with The MedTech Conference in Boston, the MedTech Insight Awards applaud those who, through their passion and unwavering commitment, are driven to cure, inform, minimise treatment burden, and make human lives better.

We are delighted that Martin Frost was recognised as the “Executive of the Year” in this year’s ceremony. Frost is one of our five founders – who came together to create 91ĸƵ in 2014, and he has led the company through a prolific five years. Most recently, he led 91ĸƵ Surgical’s record-breaking £195 million ($240 million) Series C raise, which is Europe’s largest private financing round in the medical technology sector. With Frost at the helm, 91ĸƵ has made significant strives to disrupt the medical devices sector with its global commercial roll out of Versius expected imminently.

Martin Frost, Chief Executive Officer of 91ĸƵ Surgical, commented: “I am honoured to accept this prestigious award on behalf of the whole team. In just five years, we’ve grown to four hundred people, we’ve opened a global HQ in Cambridge and, of course, we’re on the verge of launching a next-generation surgical robot. It has been a privilege to be part of this company’s story so far, and I look forward to continuing our mission to make minimal access surgery available to everyone who needs it.”

91ĸƵ believes that surgical robotic systems can increase the uptake of minimal access surgery (MAS). The benefits of MAS over open surgery are established – patients leave hospital faster, with fewer complications, in less pain and with less scarring.

Biomimicking the human arm, Versius® provides dexterity and precision to surgeons. In addition, the versatility and affordability of the system means it can be used across a broad range of MAS procedures. 91ĸƵ Surgical aims to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place around the world.

Martin Frost wins Executive of the Year award

ENDS

About 91ĸƵ Surgical Limited

91ĸƵ Surgical is a British private limited company developing the next-generation robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.

The vision behind 91ĸƵ Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.

Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.

91ĸƵ Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.

The Versius® Surgical Robotic System

Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius is able to move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.

Supporting documents
Press Office

How can we help you?

Search for: